Latest CancerVax Stories
GAITHERSBURG, Md., Aug.
BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc.
Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma.
BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVaxÂ® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr.
BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Micromet, Inc.
BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc.
BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010.
INGELHEIM, Germany and BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Boehringer Ingelheim and Micromet, Inc.
LELYSTAD and 'S-HERTOGENBOSCH, The Netherlands, April 28, 2010 /PRNewswire/ -- Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch.
BETHESDA, Md., April 19 /PRNewswire-FirstCall/ -- Micromet, Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).